Similar to 4-amino-N-[3-(dimethylamino)propyl]benzamide , Psychopharmacology
Cyclic compounds (1)
Arima · Manerix · Aurorix
Moclobemide (sold as Amira, Aurorix, Clobemix , Depnil and Manerix) is a reversible inhibitor of monoamine oxidase A (RIMA) drug primarily used to treat depression and social anxiety. It is not approved for use in the United States, but is approved in other Western countries such as the UK and Australia (TGA approved in December 2000). It is produced by affiliates of the Hoffmann–La Roche pharmaceutical company.
Agomelatine (brand names Valdoxan, Melitor, Thymanax) is an atypical antidepressant developed by the pharmaceutical company Servier. It is marketed for the treatment of major depressive disorder, primarily for its relatively favorable side effect profile: it avoids the weight gain, sexual dysfunction, and severe withdrawal associated with the most commonly used classes of antidepressants (SSRIs, SNRIs, tricyclics), while providing similar therapeutic benefit. Due to its distinctive mechanism of action, agomelatine is also studied for its effects on sleep regulation.
Phenazepam (also known in Russia as bromdihydrochlorphenylbenzodiazepine) is a benzodiazepine drug, which was developed in the Soviet Union in 1975, and now produced in Russia and some CIS countries. Phenazepam is used in the treatment of various psychiatric and neurological disorders. It can be used as a premedication before surgery as it augments the effects of anesthetics and reduces anxiety.
Chlormethiazole · Distraneurin
Clomethiazole (also called chlormethiazole) is a sedative and hypnotic originally developed by Hoffmann-La Roche in the 1930s. The drug is used in treating and preventing symptoms of acute alcohol withdrawal. It is structurally related to thiamine (vitamin B1), but acts like a sedative, hypnotic, muscle relaxant and anticonvulsant, having the same mechanism of action as traditional barbiturates..
doxylamine (562-10-7, 469-21-6)
Doxylamine is a first-generation antihistamine. It can be used by itself as a short-term sedative and in combination with other drugs to provide night-time allergy and cold relief. Doxylamine is also used in combination with the analgesics paracetamol (acetaminophen) and codeine as an analgesic/calmative preparation, and is prescribed in combination with vitamin B6 (pyridoxine) to prevent morning sickness in pregnant women.
Asendin · Défanyl · Asendis
Amoxapine, sold under the brand name Asendin among others, is a tetracyclic antidepressant (TeCA), though it is often classified as a tricyclic antidepressant (TCA). It is the N-demethylated metabolite of loxapine. Amoxapine first received marketing approval in the United States in 1992 (approximately 30 to 40 years after most of the other TCAs were introduced in the United States).
Dexedrine · Dextroamphetamine Sulfate · Dexamphetamine
Dextroamphetamine is a potent central nervous system (CNS) stimulant and amphetamine enantiomer that is prescribed for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. It is also used as an athletic performance and cognitive enhancer, and recreationally as an aphrodisiac and euphoriant. Dextroamphetamine was also used by military air and tank forces as a 'go-pill' during fatigue-inducing missions such as night-time bombing missions.
quetiapine (111974-72-2, 111974-69-7)
Quetiapine, marketed as Seroquel among others, is an atypical antipsychotic used for the treatment of schizophrenia, bipolar disorder, and major depressive disorder. It is also sometimes used as a sleep aid due to its sedating effect, but this use is not recommended. It is taken by mouth.
mirtazapine · Remeron · Rexer
Esmirtazapine (ORG-50,081) is a drug which was under development by Organon for the treatment of insomnia and vasomotor symptoms (e.g., hot flashes) associated with menopause. Esmirtazapine is the (S)-(+)-enantiomer of mirtazapine and possesses similar overall pharmacology, including inverse agonist actions at H1 and 5-HT2 receptors and antagonist actions at α2-adrenergic receptors. As of March 2010, Merck terminated internal clinical development program for esmirtazapine, for hot flashes and insomnia, for strategic reasons.